Literature DB >> 26923398

Cognitively impaired elderly exhibit insulin resistance and no memory improvement with infused insulin.

Jill K Morris1, Eric D Vidoni2, Jonathan D Mahnken3, Robert N Montgomery4, David K Johnson5, John P Thyfault6, Jeffrey M Burns2.   

Abstract

Insulin resistance is a risk factor for Alzheimer's disease (AD), although its role in AD etiology is unclear. We assessed insulin resistance using fasting and insulin-stimulated measures in 51 elderly subjects with no dementia (ND; n = 37) and with cognitive impairment (CI; n = 14). CI subjects exhibited either mild CI or AD. Fasting insulin resistance was measured using the homeostatic model assessment of insulin resistance (HOMA-IR). Insulin-stimulated glucose disposal was assessed using the hyperinsulinemic-euglycemic clamp to calculate glucose disposal rate into lean mass, the primary site of insulin-stimulated glucose disposal. Because insulin crosses the blood-brain barrier, we also assessed whether insulin infusion would improve verbal episodic memory compared to baseline. Different but equivalent versions of cognitive tests were administered in counterbalanced order in the basal and insulin-stimulated state. Groups did not differ in age or body mass index. Cognitively impaired subjects exhibited greater insulin resistance as measured at fasting (HOMA-IR; ND: 1.09 [1.1] vs. CI: 2.01 [2.3], p = 0.028) and during the hyperinsulinemic clamp (glucose disposal rate into lean mass; ND: 9.9 (4.5) vs. AD 7.2 (3.2), p = 0.040). Cognitively impaired subjects also exhibited higher fasting insulin compared to ND subjects, (CI: 8.7 [7.8] vs. ND: 4.2 [3.8] μU/mL; p = 0.023) and higher fasting amylin (CI: 24.1 [39.1] vs. 8.37 [14.2]; p = 0.050) with no difference in fasting glucose. Insulin infusion elicited a detrimental effect on one test of verbal episodic memory (Free and Cued Selective Reminding Test) in both groups (p < 0.0001) and no change in performance on an additional task (delayed logical memory). In this study, although insulin resistance was observed in cognitively impaired subjects compared to ND controls, insulin infusion did not improve memory. Furthermore, a significant correlation between HOMA-IR and glucose disposal rate was present only in ND (p = 0.0002) but not in cognitively impaired (p = 0.884) subjects, indicating potentially important physiological differences between these cohorts.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aging; Alzheimer's disease; Cognitive impairment; Hyperinsulinemia; Insulin; Insulin resistance

Mesh:

Substances:

Year:  2015        PMID: 26923398      PMCID: PMC4773916          DOI: 10.1016/j.neurobiolaging.2015.11.005

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  56 in total

1.  Glucose tolerance status and risk of dementia in the community: the Hisayama study.

Authors:  T Ohara; Y Doi; T Ninomiya; Y Hirakawa; J Hata; T Iwaki; S Kanba; Y Kiyohara
Journal:  Neurology       Date:  2011-09-20       Impact factor: 9.910

2.  Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial.

Authors:  Suzanne Craft; Laura D Baker; Thomas J Montine; Satoshi Minoshima; G Stennis Watson; Amy Claxton; Matthew Arbuckle; Maureen Callaghan; Elaine Tsai; Stephen R Plymate; Pattie S Green; James Leverenz; Donna Cross; Brooke Gerton
Journal:  Arch Neurol       Date:  2011-09-12

3.  Insulin is differentially related to cognitive decline and atrophy in Alzheimer's disease and aging.

Authors:  Jeffrey M Burns; Robyn A Honea; Eric D Vidoni; Lewis J Hutfles; William M Brooks; Russell H Swerdlow
Journal:  Biochim Biophys Acta       Date:  2011-07-01

4.  Amylin deposition in the brain: A second amyloid in Alzheimer disease?

Authors:  Kaleena Jackson; Gustavo A Barisone; Elva Diaz; Lee-way Jin; Charles DeCarli; Florin Despa
Journal:  Ann Neurol       Date:  2013-07-12       Impact factor: 10.422

5.  Characterization of insulin degrading enzyme and other amyloid-β degrading proteases in human serum: a role in Alzheimer's disease?

Authors:  Zhiheng Liu; Haihao Zhu; Guang Guang Fang; Kathryn Walsh; Mkaya Mwamburi; Benjamin Wolozin; Samer O Abdul-Hay; Tsuneya Ikezu; Malcolm A Leissring; Wei Qiao Qiu
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

6.  Neuroprotective effects of the amylin analogue pramlintide on Alzheimer's disease pathogenesis and cognition.

Authors:  Brittany L Adler; Mark Yarchoan; Hae Min Hwang; Natalia Louneva; Jeffrey A Blair; Russell Palm; Mark A Smith; Hyoung-Gon Lee; Steven E Arnold; Gemma Casadesus
Journal:  Neurobiol Aging       Date:  2013-10-11       Impact factor: 4.673

7.  Sex and ApoE genotype differences in treatment response to two doses of intranasal insulin in adults with mild cognitive impairment or Alzheimer's disease.

Authors:  Amy Claxton; Laura D Baker; Charles W Wilkinson; Emily H Trittschuh; Darla Chapman; G Stennis Watson; Brenna Cholerton; Stephen R Plymate; Matthew Arbuckle; Suzanne Craft
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

8.  Insulin resistance and gray matter volume in neurodegenerative disease.

Authors:  J K Morris; E D Vidoni; R D Perea; R Rada; D K Johnson; K Lyons; R Pahwa; J M Burns; R A Honea
Journal:  Neuroscience       Date:  2014-04-13       Impact factor: 3.590

Review 9.  Insulin: an emerging treatment for Alzheimer's disease dementia?

Authors:  Jill K Morris; Jeffrey M Burns
Journal:  Curr Neurol Neurosci Rep       Date:  2012-10       Impact factor: 5.081

10.  Beta amyloid-induced depression of hippocampal long-term potentiation is mediated through the amylin receptor.

Authors:  Ryoichi Kimura; David MacTavish; Jing Yang; David Westaway; Jack H Jhamandas
Journal:  J Neurosci       Date:  2012-11-28       Impact factor: 6.167

View more
  11 in total

Review 1.  Diabetes and Cognitive Impairment.

Authors:  Lindsay A Zilliox; Krish Chadrasekaran; Justin Y Kwan; James W Russell
Journal:  Curr Diab Rep       Date:  2016-09       Impact factor: 4.810

Review 2.  Membrane Aging as the Real Culprit of Alzheimer's Disease: Modification of a Hypothesis.

Authors:  Qiujian Yu; Chunjiu Zhong
Journal:  Neurosci Bull       Date:  2017-11-24       Impact factor: 5.203

3.  Effects of the Insulin Sensitizer Metformin in Alzheimer Disease: Pilot Data From a Randomized Placebo-controlled Crossover Study.

Authors:  Aaron M Koenig; Dawn Mechanic-Hamilton; Sharon X Xie; Martha F Combs; Anne R Cappola; Long Xie; John A Detre; David A Wolk; Steven E Arnold
Journal:  Alzheimer Dis Assoc Disord       Date:  2017 Apr-Jun       Impact factor: 2.703

4.  The serum metabolomics signature of type 2 diabetes is obscured in Alzheimer's disease.

Authors:  Jill K Morris; Brian D Piccolo; Kartik Shankar; John P Thyfault; Sean H Adams
Journal:  Am J Physiol Endocrinol Metab       Date:  2017-12-26       Impact factor: 4.310

5.  Effect of APOE ε4 Genotype on Metabolic Biomarkers in Aging and Alzheimer's Disease.

Authors:  Jill K Morris; Roxanne Adeline Z Uy; Eric D Vidoni; Heather M Wilkins; Ashley E Archer; John P Thyfault; John M Miles; Jeffrey M Burns
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

6.  Task-related fMRI BOLD response to hyperinsulinemia in healthy older adults.

Authors:  Victoria J Williams; Bianca A Trombetta; Rabab Z Jafri; Aaron M Koenig; Chase D Wennick; Becky C Carlyle; Laya Ekhlaspour; Rexford S Ahima; Steven J Russell; David H Salat; Steven E Arnold
Journal:  JCI Insight       Date:  2019-06-18

7.  Huperzine A ameliorates obesity-related cognitive performance impairments involving neuronal insulin signaling pathway in mice.

Authors:  Hong-Ying Wang; Min Wu; Jun-Ling Diao; Ji-Bin Li; Yu-Xiang Sun; Xiao-Qiu Xiao
Journal:  Acta Pharmacol Sin       Date:  2019-06-18       Impact factor: 6.150

8.  Characterization of the Meal-Stimulated Incretin Response and Relationship With Structural Brain Outcomes in Aging and Alzheimer's Disease.

Authors:  Jill K Morris; Casey S John; Zachary D Green; Heather M Wilkins; Xiaowan Wang; Ashwini Kamat; Russell S Swerdlow; Eric D Vidoni; Melissa E Petersen; Sid E O'Bryant; Robyn A Honea; Jeffrey M Burns
Journal:  Front Neurosci       Date:  2020-11-30       Impact factor: 4.677

Review 9.  Heat therapy: possible benefits for cognitive function and the aging brain.

Authors:  Alex T Von Schulze; Fengyan Deng; Jill K Morris; Paige C Geiger
Journal:  J Appl Physiol (1985)       Date:  2020-09-24

Review 10.  Repurposing Licensed Drugs for Use Against Alzheimer's Disease.

Authors:  Leslie C Norins
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.